Tengion, Inc. (TNGN)
-OTC Markets 0.69 
0.01(1.33%) 9:43AM EDT
| Prev Close: | 0.70 |
|---|
| Open: | 0.69 |
|---|
| Bid: | N/A |
|---|
| Ask: | N/A |
|---|
| 1y Target Est: | N/A |
|---|
| Beta: | 1.87 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.69 - 0.69 |
|---|
| 52wk Range: | 0.55 - 5.25 |
|---|
| Volume: | 325 |
|---|
| Avg Vol (3m): | 6,608 |
|---|
| Market Cap: | 1.89M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -7.20 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Tengion Provides Business Update and Reports First Quarter 2013 Financial ResultsPR Newswire(Wed, May 15)
- TENGION INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, May 15)
- TENGION INC Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online(Thu, Apr 4)
- TENGION INC FinancialsEDGAR Online Financials(Wed, Apr 3)
- TENGION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Mon, Apr 1)
- Tengion Receives MPA Approval of CTA for Neo-Kidney Augment Phase 1 Trial in SwedenPR Newswire(Mon, Apr 1)
- TENGION INC Files SEC form 10-K, Annual ReportEDGAR Online(Thu, Mar 28)
- Tengion Provides Business Update and Reports Fourth Quarter and Full Year 2012 Financial ResultsPR Newswire(Mon, Mar 18)
- TENGION INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Mon, Mar 18)
- Tengion to Present at 25th Annual ROTH ConferencePR Newswire(Tue, Mar 12)
- Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter and Full Year 2012 Financial Results on March 18, 2013PR Newswire(Mon, Mar 11)
- TENGION INC Files SEC form 8-K, Unregistered Sale of Equity SecuritiesEDGAR Online(Wed, Feb 20)
- TENGION INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and ExhibitsEDGAR Online(Thu, Feb 14)
- TENGION INC Files SEC form 10-Q/A, Quarterly ReportEDGAR Online(Fri, Feb 8)
- Tengion to Present at the BIO CEO & Investor ConferencePR Newswire(Tue, Feb 5)
Reports
- No Reports available for TNGN at this time.
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | N/A |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(0-00-31)
: | N/A |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | N/A |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Tengion, Inc. operates as a regenerative medicine company. The company focuses on discovering, developing, manufacturing, and commercializing a range of neo-organs or products composed of living cells with or without synthetic or natural materials...
View More